Detection of numerical aberrations of chromosomes 7 and 9 in cytologic specimens of pleural malignant mesothelioma

Cancer

Volumn 99, Issue 4, 2003, Pages 233-239

  Shin, Hyung Ju C ^a,b   Shin, Dong M ^a   Tarco, Emily ^a   Sneige, Nour ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Diagnostic adjunct; Fluorescent in situ hybridization; Malignant mesothelioma; Numerical chromosomal aberrations; Reactive benign mesothelial cells

Indexed keywords

ADULT; AGED; ARTICLE; ASPIRATION CYTOLOGY; CANCER CYTODIAGNOSIS; CHROMOSOME 7; CHROMOSOME 9; CHROMOSOME ABERRATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOLOGY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN CELL; MALE; MESOTHELIOMA; PLEURA FLUID; PLEURA MESOTHELIOMA; PLEURA TUMOR; PRIORITY JOURNAL; TETRASOMY; TRISOMY;

AGED; AGED, 80 AND OVER; ANEUPLOIDY; CHROMOSOMES, HUMAN, PAIR 7; CHROMOSOMES, HUMAN, PAIR 9; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MESOTHELIOMA; MIDDLE AGED; PLEURAL NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 0041471258     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11398     Document Type: Article

References (36)

1. Hoogsteden HC, Langerak AW, van der Kwast TH, Versnel MA, van Gelder T. Malignant pleural mesothelioma. Crit Rev Oncol Hematol. 1997;25:97-126.
2. Huncharek M. Genetic factors in the aetiology of malignant mesothelioma. Eur J Cancer. 1995;31:1741-1747.
3. Antman KH, Blum RH, Greenburger JS, Flowerdew G, Skarin AT, Canellos GP. Multimodality therapy for malignant mesothelioma based on a study of natural history. Am J Med. 1980;68:356-362.
4. Sridhar KS, Doria R, Raub WA, Thurer RJ, Saldana M. New strategies are needed in diffuse malignant mesothelioma. Cancer. 1992;70:2969-2979.
5. Martini N, McCormack PM, Bains MS, Kaiser LR, Burt ME, Hilaris BS. Pleural mesothelioma. Ann Thorac Surg. 1987;43: 113-120.
6. Oh Y, Perez-Soler R, Fossella FV, et al. Phase II study of intravenous Doxil in malignant pleural mesothelioma. Invest New Drugs. 2000;18:243-245.
7. Oels HC, Harrison EG, Carr DT, Bernatz PE. Diffuse malignant mesothelioma of the pleura: a review of 37 cases. Chest. 1971;60:564-570.
8. Sherman ME, Mark EJ. Effusion cytology in the diagnosis of malignant epithelioid and biphasic pleural mesothelioma. Arch Pathol Lab Med. 1990;114:845-851.
9. Triol JH, Conston AS, Chandler SV. Malignant mesothelioma. Cytopathology of 75 cases seen in a New Jersey community hospital. Acta Cytol. 1984;28:37-45.
10. Renshaw AA, Dean BR, Antman KH, Sugarbaker DJ, Cibas ES. The role of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma. Chest. 1997;111:106-109.
11. Fuhrman C, Duche JC, Chouaid C, et al. Use of tumor markers for differential diagnosis of mesothelioma and secondary pleural malignancies. Clin Biochem. 2000;33:405-410.
12. Cury PM, Butcher DN, Corrin B, Nicholson AG. The use of histological and immunohistochemical markers to distinguish pleural malignant mesothelioma and in situ mesothelioma from reactive mesothelial hyperplasia and reactive pleural fibrosis. J Pathol. 1999;189:251-257.
13. Kitazume H, Kitamura K, Mukai K, et al. Cytologic differential diagnosis among reactive mesothelial cells, malignant mesothelioma, and adenocarcinoma: utility of combined E-cadherin and calretinin immunostaining. Cancer (Cancer Cytopathol). 2000;90:55-60.
14. Thirkettle I, Harvey P, Hasleton PS, Ball RY, Warn RM. Immunoreactivity for cadherins, HGF/SF, met, and erbB-2 in pleural malignant mesotheliomas. Histopathology. 2000; 36:522-528.
15. Schofield K, D'Aquila T, Rimm DL. The cell adhesion molecule, E-cadherin, distinguishes mesothelial cells from carcinoma cells in fluids. Cancer (Cancer Cytopathol). 1997;81: 293-298.
16. Granados R, Cibas ES, Fletcher JA. Cytogenetic analysis of effusions from malignant mesothelioma: a diagnostic adjunct to cytology. Acta Cytol. 1994;38:711-717.
17. Tiainen M, Tammilehto L, Rautonen J, Tuomi T, Mattson K, Knuutila S. Chromosomal abnormalities and their correlation with asbestos exposure and survival in patients with mesothelioma. Br J Cancer. 1989;60:618-626.
18. Kwee WS, Veldhuizen RW, Golding RP, et al. Histologic distinction between malignant mesothelioma, benign pleural lesion and carcinoma metastasis. Evaluation of the application of morphometry combined with histochemistry and immunostaining. Virchows Arch A Pathol Anat Histol. 1982;397:287-299.
19. Frierson HF Jr, Mills SE, Legier JF. Flow cytometric analysis of ploidy in immunohistochemically confirmed examples of malignant epithelial mesothelioma. Am J Clin Pathol. 1988; 90:240-243.
20. Hafiz MA, Becker RL Jr, Mikel UV, Bahr GF. Cytophotometric determination of DNA in mesotheliomas and reactive mesothelial cells. Anal Quant Cytol Histol. 1988;10:120-126.
21. Florentine BD, Sanchez B, Raza A, et al. Detection of hyperdiploid malignant cells in body cavity effusions by fluorescence in situ hybridization on ThinPrep slides. Cancer (Cancer Cytopathol). 1997;81:299-308.
22. Cajulis RS, Frias-Hidvegi D, Yu GH, Eggena S. Detection of numerical chromosomal abnormalities by fluorescence in situ hybridization of interphase cell nuclei with chromosome-specific probes on archival cytologic samples. Diagn Cytopathol. 1996;14:178-181.
23. Kafiri G, Thomas DM, Shepherd NA, Krausz T, Lane DP, Hall PA. P53 expression is common in malignant mesotheliomas. Histopathology. 1992;21:331-334.
24. Mayall FG, Goddard H, Gibbs AR. An assessment of p53 immunostaining in the distinction between benign and malignant mesothelial proliferation using formalin fixed paraffin sections. J Pathol. 1992;168:377-381.
25. Simsir A, Fetsch P, Mehta D, Zakowski M, Abati A. E-cadherin, N-cadherin, and calretinin in pleural effusions: the good, the bad, the worthless. Diagn Cytopathol. 1999;20: 125-130.
26. Ordonez NG. Value of thyroid transcription factor-1, E-cadherin, BG8, WT1, and CD44S immunostaining in distinguishing epithelial pleural mesothelioma from pulmonary and nonpulmonary adenocarcinoma. Am J Surg Pathol. 2000;24:598-606.
27. Leers MPG, Aarts MMJ, Theunissen PHMH. E-cadherin and calretinin: a useful combination of immunohistochemical markers for differentiation between mesothelioma and metastatic adenocarcinoma. Histopathology. 1998;32:209-216.
28. Tiainen M, Tammilehto L, Mattson K, Knuutila S. Non-random chromosomal abnormalities in malignant pleural mesothelioma. Cancer Genet Cytogenet. 1988;33:251-274.
29. Voravud N, Shin DM, Ro JY, Lee JS, Hong WK, Hittelman WN. Increased polysomies of chromosome 7 and 17 during head and neck multistage tumorigenesis. Cancer Res. 1993; 53:2874-2883.
30. Hagemeijer A, Versenel MA, Van Drunen E, et al. Cytogenetic analysis of malignant mesothelioma. Cancer Genet Cytogenet. 1990;47:1-28.
31. Veltman JA, Hopman AHN, Bot FJ, Ramaekers FCS, Manni JJ. Detection of chromosomal aberrations in cytologic brush specimens from head and neck squamous cell carcinoma. Cancer (Cancer Cytopathol). 1997;81:309-314.
32. Tiainen M, Hopman A, Moesker O, et al. Interphase cytogenetics on paraffin sections of malignant mesothelioma: a comparison to conventional karyotyping and flow cytometric studies. Cancer Genet Cytogenet. 1992;62:171-179.
33. Katz RL, Caraway NP, Gu J, Jiang F, et al. Detection of chromosome 11q13 breakpoints by interphase fluorescence in situ hybridization. Am J Clin Pathol. 2000;114:248-257.
34. Segers K, Ramael M, Singh SK, Van Daele A, Weyler J, Van Marck E. Detection of numerical chromosomal aberrations in paraffin-embedded malignant pleural mesothelioma by non-isotopic in situ hybridization. J Pathol. 1995;175:219-226.
35. Johnson TM, Kuffel DG, Deward GW. Detection of hyperploid malignant cells in pleural effusions with chromosome-specific probes and fluorescence in situ hybridization. Mayo Clin Proc. 1996;71:643-648.
36. Center R, Lukeis R, Dietzsch E, Gillespie M, Garson OM. Molecular deletion of 9p sequences in non-small cell lung cancer and malignant mesothelioma. Genes Chromosomes Cancer. 1993;7:47-53.